- Previous Close
1,733.10 - Open
1,730.00 - Bid --
- Ask --
- Day's Range
1,722.60 - 1,769.60 - 52 Week Range
1,327.05 - 2,664.00 - Volume
38,239 - Avg. Volume
181,108 - Market Cap (intraday)
182.157B - Beta (5Y Monthly) --
- PE Ratio (TTM)
55.81 - EPS (TTM)
31.20 - Earnings Date --
- Forward Dividend & Yield 8.75 (0.50%)
- Ex-Dividend Date Jun 21, 2024
- 1y Target Est
1,906.80
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
www.concordbiotech.comRecent News: CONCORDBIO.NS
View MorePerformance Overview: CONCORDBIO.NS
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CONCORDBIO.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CONCORDBIO.NS
View MoreValuation Measures
Market Cap
181.24B
Enterprise Value
178.09B
Trailing P/E
55.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.94
Price/Book (mrq)
11.40
Enterprise Value/Revenue
16.64
Enterprise Value/EBITDA
36.04
Financial Highlights
Profitability and Income Statement
Profit Margin
29.96%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
10.89B
Net Income Avi to Common (ttm)
3.26B
Diluted EPS (ttm)
31.20
Balance Sheet and Cash Flow
Total Cash (mrq)
2.84B
Total Debt/Equity (mrq)
0.22%
Levered Free Cash Flow (ttm)
--